...
首页> 外文期刊>BMC Nephrology >A case report of unusually long lag time between immunotactoid glomerulopathy (itg) diagnosis and diffuse large B-cell lymphoma (DLBCL) development
【24h】

A case report of unusually long lag time between immunotactoid glomerulopathy (itg) diagnosis and diffuse large B-cell lymphoma (DLBCL) development

机译:一例报告说,类风湿性肾小球肾病(itg)诊断与弥漫性大B细胞淋巴瘤(DLBCL)发生之间的异常滞后时间异常

获取原文

摘要

Background Immunotactoid glomerulopathy (ITG) is a rare cause of proteinuria characterized by organized microtubular deposits in the glomerulus. ITG has been associated with underlying lymphoproliferative disorders and any renal impairment may be reversible with treatment of the concomitant hematologic malignancy. This case is the first reported in literature where diffuse large B cell lymphoma developed two years following the initial ITG diagnosis. Case presentation A 55-year-old woman with a history of well-controlled diabetes mellitus and thalassemia trait presented with proteinuria (830?mg/day) in 2010. Initially, she was managed with renin-angiotensin-aldosterone-system blockade. In 2012, the proteinuria worsened (4.3?g/day) and a renal biopsy showed immunotactoid glomerulopathy (Fig. 1 ). Despite extensive work up, no lymphoproliferative disorder was initially found. In January 2014, the patient presented with a soft-palate mass found on biopsy to be diffuse large B-cell lymphoma. She received 6?cycles of R-CHOP, 4?cycles of high dose methotrexate chemotherapy for CNS prophylaxis and 30?Gy of Intensity Modulated Radiation Therapy. Follow-up revealed complete remission of diffuse large B-cell lymphoma and resolution of proteinuria from the ITG. Conclusion As we recognize that patients with ITG may develop hematopoietic neoplasms, close long-term monitoring is important. Moreover, treatment of the lymphoproliferative disorder can allow for complete remission of ITG.
机译:背景技术非免疫类固醇肾小球病(ITG)是蛋白尿的罕见原因,其特征是肾小球中有组织的微管沉积物。 ITG与潜在的淋巴增生性疾病有关,任何肾脏损害在伴随血液恶性肿瘤的治疗中均可逆转。该病例是文献中首次报道的,在最初的ITG诊断后两年,弥漫性大B细胞淋巴瘤就发展了。病例报告2010年,一名55岁的女性,具有良好的糖尿病控制和地中海贫血特征,并伴有蛋白尿(830?mg /天)。最初,她接受了肾素-血管紧张素-醛固酮系统阻断治疗。在2012年,蛋白尿恶化(4.3微克/天),肾脏活检显示免疫性类脂球性肾小球病(图1)。尽管进行了大量工作,但最初并未发现淋巴增生性疾病。 2014年1月,该患者在活检时表现为软pal肿块,为弥漫性大B细胞淋巴瘤。她接受了6个疗程的R-CHOP,4个疗程的高剂量甲氨蝶呤化疗来预防中枢神经系统和30?Gy的调强放射疗法。随访发现弥散性大B细胞淋巴瘤完全缓解,ITG消除了蛋白尿。结论由于我们认识到ITG患者可能会发展为造血肿瘤,因此密切的长期监测非常重要。此外,淋巴增生性疾病的治疗可以使ITG完全缓解。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号